Flavio Rocha, Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute, shared a post on LinkedIn:
“It has been amazing to see all the drug development following the discovery of the first therapy by Dr. Brian Druker, OHSU Knight Cancer Institute for precision oncology.”
Title: FDA approves 100th small-molecule kinase inhibitor
Author: Asher Mullard
Read More about Precision Oncology on OncoDaily.